Core Viewpoint - Zhonghe Particle Medical Technology Co., Ltd. has completed its first round of over 100 million yuan equity financing, led by Zhonghe Industrial Fund Management Co., Ltd. This funding will primarily support the R&D breakthroughs, engineering advancement, registration, clinical trial layout, and market demonstration of the company's three major product lines, laying a solid foundation for future product launches [1][4]. Company Introduction - Zhonghe Particle was established in 2019 and is headquartered in Beijing. It is a self-research platform for nuclear medical equipment under the China National Nuclear Corporation. The company focuses on the value concepts of "responsibility, safety, innovation, and collaboration," aiming to become a leader in international nuclear medical equipment development [4]. Product Introduction - Zhonghe Particle's three product lines cover core aspects of nuclear medical equipment: BNCT treatment equipment, nuclear medicine imaging equipment (SPECT), and medical electron linear accelerators. All three products are currently in critical R&D and demonstration application stages, establishing a foundation for future registration, production, and large-scale implementation [5]. BNCT Equipment - Boron Neutron Capture Therapy (BNCT) is a cutting-edge radiotherapy technology aimed at difficult-to-treat tumors. It has gained global attention due to its precise energy focusing and strong adaptability to complex tumor structures. In 2024, Zhonghe Particle successfully won the bid for the BNCT equipment project at Shandong Cancer Hospital, marking the transition from R&D prototypes to deployment in demonstration hospitals [6][8]. SPECT Equipment - Zhonghe Particle's SPECT imaging device is set to receive its medical device registration certificate from the National Medical Products Administration (NMPA) in 2025, becoming the company's first officially approved high-end medical equipment product. This device features innovative SPECT/3D optical fusion imaging technology, which enhances imaging accuracy and reduces errors caused by patient positioning [9][11][12]. Medical Electron Linear Accelerator - The company is advancing the development of its medical electron linear accelerator, which integrates diagnostic CT and accelerator technologies. This design improves treatment precision and reduces patient treatment burden, aligning with global trends towards high-precision and efficient radiotherapy equipment. Collaborations with major hospitals are underway to validate the product across various clinical scenarios [13]. Conclusion - The completion of Zhonghe Particle's first round of financing represents a significant milestone in the self-sufficiency of China's nuclear medical equipment sector. The three business lines—BNCT, SPECT, and linear accelerators—cover critical areas in advanced radiotherapy, nuclear medicine diagnosis, and precision radiotherapy, reflecting the ongoing accumulation of capabilities in R&D, manufacturing processes, and hospital validation systems [14].